Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: Report of 52 cases and literature review

Kazuhiro Matsumoto, Masayuki Hagiwara, Nozomi Hayakawa, Nobuyuki Tanaka, Yujiro Ito, Takahiro Maeda, Akiharu Ninomiya, Hirohiko Nagata, So Nakamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2%) achieved more than 50% reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2%). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3%) showed a positive response to treatment, compared to only three of 37 patients (8.1%) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.

Original languageEnglish
Pages (from-to)3645-3649
Number of pages5
JournalAsian Pacific Journal of Cancer Prevention
Volume15
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Recurrence
Prostate-Specific Antigen
Nonsteroidal Anti-Androgens
Androgen Antagonists
Therapeutics
Castration
Chlormadinone Acetate
Flutamide
PubMed
Medical Records
Cohort Studies
Databases
Serum
Neoplasms

Keywords

  • Alternative antiandrogen
  • CRPC
  • Hormonal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Public Health, Environmental and Occupational Health
  • Epidemiology
  • Medicine(all)

Cite this

Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy : Report of 52 cases and literature review. / Matsumoto, Kazuhiro; Hagiwara, Masayuki; Hayakawa, Nozomi; Tanaka, Nobuyuki; Ito, Yujiro; Maeda, Takahiro; Ninomiya, Akiharu; Nagata, Hirohiko; Nakamura, So.

In: Asian Pacific Journal of Cancer Prevention, Vol. 15, No. 8, 2014, p. 3645-3649.

Research output: Contribution to journalArticle

Matsumoto, Kazuhiro ; Hagiwara, Masayuki ; Hayakawa, Nozomi ; Tanaka, Nobuyuki ; Ito, Yujiro ; Maeda, Takahiro ; Ninomiya, Akiharu ; Nagata, Hirohiko ; Nakamura, So. / Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy : Report of 52 cases and literature review. In: Asian Pacific Journal of Cancer Prevention. 2014 ; Vol. 15, No. 8. pp. 3645-3649.
@article{9091adf354b14122a74e340963671904,
title = "Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: Report of 52 cases and literature review",
abstract = "The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2{\%}) achieved more than 50{\%} reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2{\%}). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3{\%}) showed a positive response to treatment, compared to only three of 37 patients (8.1{\%}) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.",
keywords = "Alternative antiandrogen, CRPC, Hormonal therapy, Prostate cancer",
author = "Kazuhiro Matsumoto and Masayuki Hagiwara and Nozomi Hayakawa and Nobuyuki Tanaka and Yujiro Ito and Takahiro Maeda and Akiharu Ninomiya and Hirohiko Nagata and So Nakamura",
year = "2014",
doi = "10.7314/APJCP.2014.15.8.3645",
language = "English",
volume = "15",
pages = "3645--3649",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "8",

}

TY - JOUR

T1 - Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy

T2 - Report of 52 cases and literature review

AU - Matsumoto, Kazuhiro

AU - Hagiwara, Masayuki

AU - Hayakawa, Nozomi

AU - Tanaka, Nobuyuki

AU - Ito, Yujiro

AU - Maeda, Takahiro

AU - Ninomiya, Akiharu

AU - Nagata, Hirohiko

AU - Nakamura, So

PY - 2014

Y1 - 2014

N2 - The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2%) achieved more than 50% reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2%). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3%) showed a positive response to treatment, compared to only three of 37 patients (8.1%) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.

AB - The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English. Including our cases, this provided a total of 102 cases for analysis. In our study cohort, 11 cases (21.2%) achieved more than 50% reduction of serum prostate-specific antigen (PSA) on initiation of third-line CAB. We found that third-line CAB with nonsteroidal antiandrogen after second-line CAB with steroidal antiandrogen exhibited favorable results, with a positive response in six of 13 patients (46.2%). Cumulative analysis findings were comparable. Regarding the timing of third-line CAB administration, 15 patients had started at a PSA equal to or less than 4.0 ng/ml, and eight of them (53.3%) showed a positive response to treatment, compared to only three of 37 patients (8.1%) whose PSA at the initiation of third-line therapy was higher than 4.0 ng/ml (p<0.001). We conclude that third-line CAB with nonsteroidal antiandrogen would be particularly useful for patients whose cancer progressed after second-line CAB with steroidal antiandrogen. The timing of treatment seems to be important because the higher the PSA at the start of third-line therapy, the lower the PSA response rate.

KW - Alternative antiandrogen

KW - CRPC

KW - Hormonal therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84901989721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901989721&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2014.15.8.3645

DO - 10.7314/APJCP.2014.15.8.3645

M3 - Article

C2 - 24870772

AN - SCOPUS:84901989721

VL - 15

SP - 3645

EP - 3649

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 8

ER -